NORTHVALE, N.J., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company")
(OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results
for the six months ended September 30, 2016, the second quarter of its 2017 fiscal year.
Consolidated revenues for the second quarter were $2.7 million, consisting of $2.0 million in manufacturing
revenues and $0.7 million in license fees. Consolidated revenues for the quarter decreased by approximately 7% as compared to
revenues for the second quarter of the prior year primarily due to timing differences in shipments. On a year-to-date basis,
consolidated revenues were $6.0 million for the six months ended September 30, 2016, an increase of approximately 18% over revenues
for the comparable period of the prior year. The primary driver of this growth is the continued expansion and
establishment of Elite’s generic product lines in the market.
“We delivered solid quarterly performance”, commented Nasrat Hakim, Elite’s President and CEO. “Annualized
revenues exceed $10 million, and we continue to execute on our growth strategy and the development of our pipeline of future
products.”
Conference Call Information
Elite's management will host a conference call to discuss the second quarter of fiscal year 2017 financial results and provide an
update on recent business developments. Stockholder questions should be summited to the company in advance of the call.
The financial statements can be viewed for Elite’s Second Quarter of Fiscal Year 2017 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological
abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release
drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma,
Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold,
additional approved products pending manufacturing site transfer and the NDA for SequestOx™, for which it just received the
CRL from the FDA. Elite’s lead pipeline products include abuse-deterrent opioids which utilize the Company’s patented
proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the
treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision
of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract
manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility
for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may
have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements
involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the transfers of the ANDAs
or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not
under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from
the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking
statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, the steps Elite
may take as a result of the CRL, the results of an End of Review Meeting and what actions the FDA may require of Elite in order to
obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and
other factors, including, without limitation, Elite’s ability to obtain sufficient funding under the LPC Agreement or from other
sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug
Administration and other regulatory authorities, intellectual property protections and defenses, and the Elite’s ability to operate
as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms
10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact: For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222 Dianne@elitepharma.com www.elitepharma.com
